Inhibitors of the sodium-glucose cotransporter 2 (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RA) have been studied and trialled in type 2 diabetes with an overwhelming body of evidence supporting their use in type 2 diabetes [10]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.